Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors

Lancet. 2000 Sep 16;356(9234):1003-4. doi: 10.1016/S0140-6736(00)02697-0.

Abstract

We describe four patients with galactorrhoea as an isolated endocrine abnormality after use of protease inhibitors (PIs) as part of both highly active antiretroviral therapy (HAART) and postexposure prophylaxis (PEP). This reaction may be a direct effect of PIs or may be indirectly mediated by the effect of PIs on the cytochrome P450 system, thus potentiating the dopamine antagonist effects of other drugs.

Publication types

  • Letter

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Cytochrome P-450 Enzyme System / drug effects
  • Female
  • Galactorrhea / chemically induced*
  • HIV Infections / drug therapy*
  • HIV Infections / etiology
  • HIV Infections / prevention & control
  • HIV-1*
  • Humans
  • Hyperprolactinemia / chemically induced*
  • Needlestick Injuries
  • Protease Inhibitors / adverse effects*
  • Rape

Substances

  • Anti-HIV Agents
  • Protease Inhibitors
  • Cytochrome P-450 Enzyme System